Last updated: July 31, 2026
Glyburide/metformin hydrochloride is a mature, low-cost oral combination for type 2 diabetes. Its clinical role is established, but its commercial position is weakening. The product has no meaningful branded patent barrier in the United States, faces broad generic competition, and has limited late-stage clinical-development activity. Future demand is likely to remain concentrated in price-sensitive markets and patients requiring a low-cost alternative to newer glucose-lowering therapies.
The combination's main commercial constraints are hypoglycemia, weight gain, renal restrictions, and competition from metformin combined with DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. The principal residual opportunity is fixed-dose convenience in markets where drug cost and access dominate treatment selection.
What is glyburide/metformin hydrochloride used for?
Glyburide/metformin combines a biguanide, metformin, with a sulfonylurea, glyburide, also called glibenclamide outside the United States.
| Attribute |
Glyburide/metformin |
| Therapeutic class |
Oral antihyperglycemic combination |
| Primary indication |
Type 2 diabetes mellitus |
| Mechanism |
Reduced hepatic glucose production plus increased pancreatic insulin secretion |
| Common U.S. strengths |
1.25/250 mg, 2.5/500 mg, 5/500 mg; generic products may vary |
| Administration |
With meals; titration is individualized |
| Main safety risks |
Hypoglycemia, gastrointestinal effects, lactic acidosis risk from metformin, weight gain |
| Key restrictions |
Renal impairment, metabolic acidosis, significant hepatic disease, acute hypoxic states |
| FDA status |
Approved combination product; widely available through generic manufacturers |
Glyburide is more likely than some other sulfonylureas to cause prolonged hypoglycemia, particularly in older adults and patients with renal impairment. The American Diabetes Association identifies sulfonylureas as low-cost drugs but places them behind agents with lower hypoglycemia risk for many patients (American Diabetes Association Professional Practice Committee, 2024).
What clinical evidence supports glyburide/metformin?
The clinical rationale is based on complementary pharmacology and older comparative trials rather than a new development program.
Combination efficacy
Metformin reduces hepatic glucose production and improves insulin sensitivity. Glyburide stimulates pancreatic insulin release. The combination can reduce hemoglobin A1c more than either component used alone in patients whose glycemic control is inadequate with monotherapy.
The principal evidence base includes:
- Randomized trials comparing glyburide/metformin with glyburide or metformin monotherapy.
- Studies of patients inadequately controlled on sulfonylurea or metformin alone.
- Older combination-therapy studies conducted before widespread use of SGLT2 inhibitors and GLP-1 receptor agonists.
- Long-term type 2 diabetes evidence supporting metformin as an initial therapy and sulfonylureas as low-cost glucose-lowering agents.
The United Kingdom Prospective Diabetes Study established the importance of glucose control and showed clinical benefits from intensive treatment in newly diagnosed type 2 diabetes. It did not establish the modern fixed-dose glyburide/metformin product as a differentiated therapy, but it supports the broader role of metformin and sulfonylurea-based treatment in the historical treatment pathway (UK Prospective Diabetes Study Group, 1998a, 1998b).
Clinical limitations
The product has a narrow value proposition compared with newer combinations.
| Clinical factor |
Commercial implication |
| Effective A1c reduction |
Supports use where cost is the primary consideration |
| Hypoglycemia risk |
Limits use in older adults, patients with irregular meals, and patients with renal dysfunction |
| Weight gain |
Reduces attractiveness compared with GLP-1 and SGLT2 therapies |
| No proven cardiovascular or renal-protection advantage |
Weakens positioning against empagliflozin, dapagliflozin, semaglutide and related agents |
| Metformin gastrointestinal intolerance |
Can reduce persistence |
| Renal dosing restrictions |
Narrows eligible population |
| Low acquisition cost |
Preserves demand in public-sector and lower-income markets |
What clinical trials are evaluating glyburide/metformin?
Glyburide/metformin has no visible late-stage innovation program comparable with newer diabetes medicines. ClinicalTrials.gov contains historical studies involving glyburide, metformin, or combination therapy, but the combination is not a major active trial platform for new indications, cardiovascular outcomes, or disease modification (ClinicalTrials.gov, 2024).
Current research activity is more likely to involve:
- Comparative effectiveness in real-world diabetes populations.
- Use of sulfonylureas in resource-limited settings.
- Pregnancy-related diabetes research involving glyburide or metformin as separate therapies.
- Adherence and treatment-intensification studies.
- Cost-effectiveness analyses of older oral agents.
Pregnancy is a separate clinical area. Glyburide and metformin have each been studied in gestational diabetes, but those studies do not establish glyburide/metformin fixed-dose combination therapy as a preferred pregnancy product. Treatment recommendations vary by jurisdiction and clinical circumstances.
What is the FDA regulatory status of glyburide/metformin?
The U.S. Food and Drug Administration approved Glucovance, the original branded glyburide/metformin product, in 2000 for adults with type 2 diabetes inadequately controlled by glyburide or metformin monotherapy, or as initial therapy in selected patients (U.S. Food and Drug Administration, 2000).
The current regulatory profile is mature:
| Regulatory issue |
Status |
| New drug approval |
Historical approval for Glucovance |
| Generic availability |
Broadly available |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Not commercially relevant to the mature product |
| Orphan exclusivity |
Not applicable |
| Biosimilar pathway |
Not applicable; this is a small-molecule drug |
| Current development status |
Generic maintenance and lifecycle manufacturing |
The product is regulated through abbreviated new drug applications for generic versions. There is no biologic manufacturing or biosimilar substitution issue.
What is the Orange Book status of glyburide/metformin?
The Orange Book remains the relevant source for approved reference products, therapeutic equivalence evaluations, and listed patents. Glyburide/metformin is a small-molecule combination product, so its competitive framework is based on generic substitution and ANDA approvals rather than biosimilar interchangeability (U.S. Food and Drug Administration, 2024a).
The commercial significance of the Orange Book record is limited because:
- The original branded exclusivity period has expired.
- Generic products are established.
- The product has no meaningful market-wide barrier based on a current composition-of-matter patent.
- Any remaining listing activity would need to be assessed at the specific reference-product and dosage-form level.
- Generic competition is determined primarily by approval status, manufacturing capacity, pricing, and supply reliability.
What patents protect glyburide/metformin?
The original combination patent estate no longer provides a practical U.S. exclusivity barrier.
| Patent category |
Current commercial relevance |
| Glyburide composition patents |
Expired |
| Metformin composition patents |
Expired |
| Fixed-dose combination patents |
Expired or commercially nonblocking |
| Original Glucovance exclusivity |
Expired |
| Formulation patents |
Limited relevance; no broad market barrier identified |
| Method-of-use patents |
No material exclusivity for standard type 2 diabetes treatment |
| Manufacturing patents |
Potentially relevant to individual suppliers, not to the market as a whole |
| Patent litigation risk |
Low relative to protected diabetes brands |
A generic manufacturer could still face ordinary risks involving formulation specifications, process patents, regulatory deficiencies, or product-quality disputes. Those risks do not restore brand-level exclusivity. The key entry requirement is an approvable ANDA demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product.
When does glyburide/metformin lose exclusivity?
Glyburide/metformin lost practical exclusivity years ago. The original Glucovance approval dates from 2000, and generic competition has been established for many years. There is no commercially meaningful U.S. exclusivity cliff remaining for the standard product.
The relevant competitive timeline is therefore:
| Period |
Market event |
| 2000 |
FDA approval of Glucovance |
| Early 2000s |
Generic development and entry pathway opens |
| Following years |
Multiple generic suppliers enter |
| 2010s |
Price erosion and substitution become established |
| 2020s |
Mature generic market with limited branded differentiation |
| 2024-2030 |
Continued low-cost use, mainly in price-sensitive segments |
How many patents cover glyburide/metformin?
No single patent count provides a reliable measure of commercial protection. Patent databases contain historical patents, expired patents, formulation filings, foreign equivalents, and patents covering individual ingredients rather than the marketed combination.
For business analysis, the relevant conclusion is that the product has no effective blocking patent estate for ordinary U.S. generic entry. Patent volume is therefore less important than:
- FDA approval status.
- Therapeutic-equivalence rating.
- Manufacturing cost.
- Supply continuity.
- State substitution rules.
- Pharmacy benefit manager contracting.
- Procurement tenders in emerging markets.
What patent litigation affects glyburide/metformin?
Glyburide/metformin is not associated with a current, high-value Paragraph IV litigation campaign comparable with branded GLP-1, SGLT2, insulin, or oncology products.
Paragraph IV risk is low because the core product is generic and unprotected. Any litigation is more likely to concern:
- A particular ANDA applicant.
- A manufacturing process.
- Product quality or current good manufacturing practice compliance.
- A narrow formulation claim.
- A commercial dispute between suppliers.
The absence of major litigation reduces launch uncertainty for new generic manufacturers, but it also limits pricing power because the market is already heavily commoditized.
Which companies are challenging glyburide/metformin?
The market is challenged by generic manufacturers rather than by a defined branded challenger. U.S. supply has historically included products from large generic companies and contract manufacturers, with availability varying by strength, dosage form, manufacturing site, and pharmacy inventory.
The competitive field includes:
- Established U.S. generic suppliers.
- Indian generic manufacturers.
- Regional manufacturers in Latin America, Asia, Africa, and the Middle East.
- Private-label distributors sourcing from approved manufacturers.
- Combination-product manufacturers serving public-sector tenders.
Supplier concentration can change quickly because low-margin products may be discontinued or placed on intermittent supply. The number of approved suppliers does not always equal the number of manufacturers actively shipping product.
What formulations are protected by glyburide/metformin patents?
The commercial product is generally an immediate-release fixed-dose tablet. Formulation differentiation is limited.
Potential formulation categories include:
- Immediate-release tablets.
- Different glyburide-to-metformin dose ratios.
- Scored or unscored tablets.
- Film-coated tablets.
- Packaging configurations.
- Manufacturing processes intended to improve content uniformity or dissolution.
These attributes can support regulatory approval or supplier differentiation but do not create a durable market barrier unless a valid, enforceable patent remains listed and relevant to the approved product. Extended-release innovation is more commercially meaningful for metformin alone than for the glyburide/metformin fixed-dose combination.
How does glyburide/metformin compare with competing diabetes combinations?
| Product class |
Relative advantage |
Relative disadvantage |
| Glyburide/metformin |
Very low cost; familiar oral therapy |
Hypoglycemia, weight gain, no established cardiorenal benefit |
| Glipizide/metformin |
Lower prolonged-hypoglycemia concern than glyburide in some patients |
Same broad sulfonylurea limitations |
| Sitagliptin/metformin |
Lower hypoglycemia risk; established combination use |
Higher cost; limited weight loss |
| Empagliflozin/metformin |
Cardiorenal outcomes and oral dosing |
Higher cost; genital infections and volume-related risks |
| Dapagliflozin/metformin |
Cardiorenal positioning and oral dosing |
Higher cost and class-specific adverse effects |
| GLP-1 receptor agonist plus metformin |
Weight loss and strong glucose lowering |
Injectable or higher-cost oral options; gastrointestinal effects |
| Insulin plus metformin |
High efficacy in advanced disease |
Hypoglycemia, weight gain, administration burden |
Guidelines increasingly prioritize treatment selection according to cardiovascular disease, heart failure, chronic kidney disease, obesity, hypoglycemia risk, and patient preference. That approach limits the role of glyburide/metformin to patients without a compelling indication for newer agents and those who require a low-cost regimen (American Diabetes Association Professional Practice Committee, 2024).
What is the market size and revenue exposure for glyburide/metformin?
Glyburide/metformin is a small, mature segment of the global diabetes market. Public companies generally do not report the product as a separate revenue category, preventing a dependable product-level revenue estimate from company filings.
Its revenue profile has four characteristics:
- Low average selling prices.
- High prescription volume relative to revenue.
- Severe generic price competition.
- Limited opportunity for premium pricing.
Revenue exposure is more relevant for manufacturers with broad generic portfolios than for originator pharmaceutical companies. A supplier's risk is operational rather than patent-related. Loss of a manufacturing site, a regulatory warning, or withdrawal from a tender can materially affect unit supply, while market-wide price increases are difficult to sustain.
What is the glyburide/metformin market projection for 2024-2030?
The base-case outlook is gradual volume contraction in high-income markets and stable-to-modest growth in selected emerging markets.
| Market driver |
2024-2030 direction |
| U.S. branded sales |
Minimal |
| U.S. generic volume |
Stable to declining |
| U.S. generic price |
Downward or flat |
| Use in older adults |
Declining because of hypoglycemia concerns |
| Use in price-sensitive markets |
Stable or modestly increasing |
| Fixed-dose convenience demand |
Persistent but limited |
| Competition from SGLT2 and GLP-1 therapies |
Increasing |
| Patent-related disruption |
Low |
| Manufacturing and supply risk |
Moderate |
Base-case projection
A reasonable commercial base case is:
- Developed-market volume decline of roughly 3% to 6% annually.
- Emerging-market volume growth of roughly 1% to 4% annually where diagnosis and treatment access expand.
- Global revenue remaining flat to declining because volume growth is offset by generic price erosion.
- No material recovery in branded pricing.
- Continued use in formularies and tenders that prioritize acquisition cost.
This projection assumes no major safety withdrawal, no broad reimbursement shift favoring the product, and continued availability of metformin, glyburide, and approved fixed-dose tablets.
Upside scenario
The main upside case is not a branded launch. It is increased use in lower-income health systems, public procurement programs, and markets where newer diabetes medicines remain unaffordable. A manufacturer with reliable supply, competitive tenders, and local registration could gain share even in a declining global segment.
Downside scenario
The downside case involves accelerated replacement by metformin plus SGLT2 inhibitors, GLP-1 therapies, or safer sulfonylureas; additional restrictions in older adults; and manufacturing discontinuations that reduce availability of specific strengths.
What generic entry risks exist for glyburide/metformin?
Generic entry risk is high because there is little patent protection. The principal risks are commercial:
- Price compression from multiple suppliers.
- Low profitability at small manufacturing scale.
- API sourcing constraints.
- Batch failures or FDA compliance actions.
- Discontinuation of low-volume strengths.
- Pharmacy substitution toward alternative metformin combinations.
- Hospital and government tender losses.
Manufacturing know-how is not a major technical barrier. The product requires established tablet manufacturing, control of dose uniformity, dissolution, stability, and bioequivalence. API quality and supply reliability may matter more than proprietary formulation technology.
What licensing deals exist for glyburide/metformin?
No major current licensing transaction is central to the global commercial position of glyburide/metformin. The product's mature generic status reduces the economic rationale for licensing a proprietary platform or regional commercialization right.
Potential transactions are more likely to involve:
- Portfolio acquisitions by generic companies.
- Regional supply and distribution agreements.
- Contract manufacturing.
- Government procurement arrangements.
- Product rights bundled with broader diabetes portfolios.
These transactions generally do not create a new exclusivity period.
What is the competitive outlook for glyburide/metformin?
The product will remain commercially available but strategically peripheral in markets with broad access to newer diabetes medicines. Its strongest defenses are low cost, oral administration, physician familiarity, and fixed-dose convenience.
Its weakest points are clinical safety and lack of differentiated outcomes. The product is unlikely to support substantial R&D investment, premium pricing, or significant patent litigation. The most credible commercial strategy is efficient generic manufacturing and reliable distribution rather than clinical repositioning.
Key Takeaways
- Glyburide/metformin is an established oral therapy for type 2 diabetes with broad generic availability.
- The combination has no meaningful remaining U.S. exclusivity barrier.
- Current clinical activity is limited, with no major late-stage development program.
- Hypoglycemia, weight gain, renal restrictions, and lack of cardiorenal benefits limit use.
- Generic competition creates high entry risk and persistent price pressure.
- Demand should remain stable in cost-sensitive markets but decline in many developed markets.
- A 3% to 6% annual developed-market volume decline is a reasonable base-case assumption through 2030.
- Manufacturing reliability, tender access, and regulatory compliance matter more than patent strength.
- Biosimilar risk is irrelevant because glyburide/metformin is a small-molecule product.
- No major current licensing or Paragraph IV litigation event defines the market.
FAQs
Is glyburide/metformin still available in the United States?
Yes. Generic glyburide/metformin tablets remain available, although supply can vary by strength, manufacturer, and pharmacy inventory.
Is glyburide/metformin safer than metformin alone?
No. Adding glyburide increases glucose-lowering potency but also increases hypoglycemia and weight-gain risk compared with metformin alone.
Does glyburide/metformin have biosimilar competition?
No. Biosimilars apply to biologic products. Glyburide/metformin is a chemically synthesized small-molecule combination and competes through generic ANDA approvals.
Can a new company obtain market exclusivity for glyburide/metformin?
A standard immediate-release product is unlikely to obtain meaningful market exclusivity. A novel formulation or delivery system could potentially receive limited protection if it satisfies applicable patent and regulatory requirements, but the existing product has little commercial differentiation.
Will GLP-1 and SGLT2 drugs eliminate glyburide/metformin demand?
No. They will continue to displace the combination in patients who can access and afford them, but glyburide/metformin should retain demand in low-cost formularies, public tenders, and markets with limited access to newer therapies.
References
-
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.
-
ClinicalTrials.gov. (2024). Search results for glyburide and metformin hydrochloride. U.S. National Library of Medicine.
-
UK Prospective Diabetes Study Group. (1998a). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet, 352(9131), 837-853.
-
UK Prospective Diabetes Study Group. (1998b). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. The Lancet, 352(9131), 854-865.
-
U.S. Food and Drug Administration. (2000). Glucovance label. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.
